Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Change in Receivables (2016 - 2025)

Standard Biotools (LAB) has disclosed Change in Receivables for 16 consecutive years, with $5.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 111.46% to $5.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 0.0% change, with the full-year FY2024 number at -$9.0 million, down 399.8% from a year prior.
  • Change in Receivables was $5.8 million for Q3 2025 at Standard Biotools, up from $276000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $6.2 million in Q3 2022 to a low of -$9.8 million in Q1 2021.
  • A 5-year average of -$298789.5 and a median of $276000.0 in 2025 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: crashed 1128.3% in 2022, then surged 6013.33% in 2023.
  • Standard Biotools' Change in Receivables stood at $4.7 million in 2021, then tumbled by 98.73% to $60000.0 in 2022, then soared by 6013.33% to $3.7 million in 2023, then tumbled by 282.52% to -$6.7 million in 2024, then soared by 186.54% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Change in Receivables are $5.8 million (Q3 2025), $276000.0 (Q2 2025), and $2.0 million (Q1 2025).